Reliability, repeatability and sensitivity to change of externally and self-paced walking tests in COPD patients

Respiratory Medicine

Volumn 97, Issue 4, 2003, Pages 407-414

  Eiser, Noemi ^a   Willsher, D ^a   Dore C J ^b  

^a UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

2 min walking test; 6 min walking test; COPD; Incremental shuttle test

Indexed keywords

BRONCHODILATING AGENT; STEROID;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DYSPNEA; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY; SCORING SYSTEM; SENSITIVITY ANALYSIS; TASK PERFORMANCE; TIME; TREATMENT OUTCOME; WALKING;

EID: 0037386127     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2002.1462     Document Type: Article

References (36)

1. Maltbaek N, Garsdal P, Christensen H, et al. Effects of oral terbutaline in chronic airflow obstruction. Chest 1989; 95: 1248-1252.
2. Wolkove N, Dajczman E, Colacone A, et al. The relationship between pulmonary function and dyspnea in obstructive lung disease. Chest 1989; 96: 1247-1251.
3. Evald T, Keittlmann S, Sindrup JH, et al. The effect of inhaled terbutaline on FEVI, FVC, dyspnoea and walking distance in patients with chronic obstructive lung disease. Resp Med 1992; 86: 93-96.
4. Cooper KH. Method of assessing maximal oxygen intake; the correlation between field and treadmill exercise. JAMA 1968; 203: 201-204.
5. McGavin CR, Gupta SP, McHardy GJR. Twelve-minute walking test for assessing disability in chronic bronchitis. Br Med J 1976; 1: 822-823.
6. Butland RJA, Pang J, Gross ER, et al. Two-, six- and 12-minute walking tests in respiratory disease. Br Med J 1982; 282: 1607-1608.
7. Knox AJ, Morrison JFJ, Muers MF. Reproducibility of walking test results in chronic obstructive airways disease. Thorax 1988; 43: 388-392.
8. Pride NB, Vermeire P, Allegra L. Diagnostic labels applied to a model case history of chronic airflow obstruction. Response to a questionnaire in II North American and Western European countries. Eur Respir J 1989; 2: 702-709.
9. Singh SJ, Morgan MDL, Scott S, et al. Development of a shuttle walking test of disability in patients with chronic airways obstruction, Thorax 1992; 47: 1019-1024.
10. Singh SJ, Morgan MDL, Hardman AE. Comparison of oxygen uptake during a conventional treadmill test and the shuttle walking test in chronic airflow limitation. Eur Respir J 1994; 7: 2016-2020.
11. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment of chronic obstructive pulmonary disease (COPD). The European Society Task Force. Eur Respir J 1995; 8: 1398-1420.
12. Guyatt GH, Pugsley SO, Sullivan MJ, et al. Effect of encouragement on walking test performance. Thorax 1984; 39: 818-822.
13. Borg GAV. Psychophysical basis of perceived exertion. Med Sci Sports Exerc 1982; 14: 377-381.
14. Genstat 5 Committee. Genstat 5 Release 3 Reference Manual. Oxford: Clarendon Press, 1993.
15. Eliasson O, Degraff AC. The use of criteria for reversibility and obstruction to define patient groups for bronchodilator trials. Am Rev Respir Dis 1985; 132: 858-864.
16. Hay JG, Stone P, Carter J, et al. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 1992; 5: 659-664.
17. Brand PLP, Quanjer PH, Postma DS, et al. Interpretation of bronchodilator response in patients with obstructive airways disease. Thorax 1992; 47: 429-436.
18. Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. Eur Respir J 1999; 14: 270-274.
19. Anthonisen NR, Wright EC and the IPPB trial group. Bronchodilator response in chronic pulmonary disease. Am Rev Respir Dis 1986; 133: 814-819.
20. Lindgren S, Bake B, Larsson S. Day to day variation of bronchodilatory response to an inhaled beta2-stimulant in asthmatics. Bull Eur Physiopath Respir 1988; 23: 607-611.
21. Weir DC, Burge SP. Measures of reversibility of response to bronchodilators in chronic airflow obstruction: relation to airway calibre. Thorax 1991; 46: 43-45.
22. 1. Eur Respir J 1992; 5: 976-981.
23. Kerstjens HAM, Brand PL, Quanjer PH, et al. Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Thorax 1993; 48: 722-729.
24. Mahler DA, Matthay RA, Snyder PE, et al. Sustained release theophylline reduced dyspnea in obstructive lung disease. Am Rev Respir Dis 1985; 131: 22-25.
25. Tashkin DP, Ashutosh K, Bleeker ER, et al. Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. Am J Med 1986; 81 (Suppl. 5A) 81-90.
26. Redelmeier DA, Bayoumi AM, Goldstein RS, et al. Interpreting small differences in functional status: the six minute walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997; 155: 1278-1282.
27. Foglio K, Carone M, Pagani M, et al. Physiological and symptom determinants of exercise performance in patients with chronic airways obstruction. Respir Med 2000; 94: 256-263.
28. Leitch AG, Hopkin JM, Ellis DA, et al. The effect of ipratropium bromide and salbutamol on exercise tolerance in chronic bronchitis. Thorax 1978; 33: 711-713.
29. McGavin CR, Artinli M, Naoe H, et al. Dyspnoea, disability and distance walked: comparison of estimates of exercise performance in respiratory disease. Brit Med J 1978; 2: 241-243.
30. Mungall IPF, Hainsworth R. Assessment of respiratory function in patients with chronic obstructive airways disease. Thorax 1979; 34: 254-258.
31. Bergen R, Smith D. Effect of inhaled metaproterenol on exercise performance in patients with stable "fixed" airways obstruction. Am Rev Respir Dis 1988; 138: 624-629.
32. Maltbaek N, Larsen, KR, Tonnesen P, et al. Shuttle walk and 6 minute walking distance in patients with COPD. Eur Respir J 1999; 13: 383s.
33. Lim J, ZuWallack R. A comparison of the six minute and shuttle walk tests in assessing dyspnea and handicap in patients with obstructive airways disease. Eur Respir J 1999; 13: 422s.
34. Stark RD. Dyspnoea: assessment and pharmacological manipulation. Eur Respir J 1988; 1: 280-287.
35. Stark RD, Gambles SA, Chatterjee SS. An exercise test to assess clinical dyspnoea: estimation of reproducibility and sensitivity. Br J Dis Chest 1982; 76: 269-278.
36. Eiser N, Denman WT, West C, et al. Oral diamorphine; lack of effect on dyspnoea and exercise tolerance in the "pink puffer" syndrome. Eur Respir J 1991; 4: 926-931.